Can Bosutinib treat breast cancer?

Bosutinib is mainly used to treat chronic myeloid leukemia (CML) and is a tyrosine kinase inhibitor. Currently, bosutinib is not approved for the treatment of breast cancer.

Breast cancer is a common type of cancer, and its treatment options usually include surgery, radiation therapy, chemotherapy, hormone therapy and targeted therapy. Targeted therapy is a relatively novel treatment strategy that focuses on specific molecules or pathways to inhibit the growth and division of cancer cells.

Currently, some other targeted therapies, such as Herceptin (Herceptin) and pembrolizumab (Pertuzumab), have It has been shown to have significant efficacy in the treatment of breast cancer, particularly in patients expressing human epidermal growth factor receptor 2 (HER2). HER2Positive breast cancer is a subtype with a specific biomarker, and drugs that target this biomarker play an important role in its treatment.

Despite its success in tyrosine kinase inhibition, bosutinib is still in its early stages of development in breast cancer and has not yet achieved clear clinical approval. Research in the field of breast cancer treatment is still evolving, and new targeted therapeutic drugs and treatment strategies are gradually emerging.

Bosutinib is not yet available in China, so patients cannot purchase it domestically and need to purchase it through overseas channels. There are original drugs and generic drugs of bosutinib abroad. The original drugs include the Turkish original drug and the European version of the original drug. The Turkish version of the original drug costs about 2,000 to 3,000 yuan, and the European version of the original drug costs about 30,000 yuan. In addition, there are cheaper generic drugs, which cost more than one thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.